Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xuanfeizhisuheji is a Traditional Chinese Medicine (TCM) oral liquid formulation primarily indicated for the treatment of cough, phlegm, and chest tightness associated with acute bronchitis and post-infection cough (PIC). Developed and manufactured by Gansu Puan Pharmaceutical, the formulation is based on a traditional herbal recipe designed to ventilate the lungs, resolve phlegm, and suppress cough. Its primary herbal components include *Schizonepeta tenuifolia*, *Peucedanum praeruptorum*, *Platycodon grandiflorum*, *Aster tataricus*, *Tussilago farfara*, *Citrus reticulata*, and *Glycyrrhiza uralensis*. Clinical studies, including those registered under ChiCTR2100053411 and conducted at institutions like the China-Japan Friendship Hospital, have evaluated its efficacy in managing respiratory symptoms following viral infections and in acute inflammatory conditions of the bronchial tree.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xuanfeizhisuheji.